In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:

• The clinical implications of using DLL3 as a therapeutic target
• The impact of emerging DLL3-targeted therapies on evolving treatment paradigms
• How to incorporate DLL3-based treatments into clinical practice

Presenters:

Daniel Morgensztern, MD
Professor of Medicine
Clinical Director of Thoracic Oncology
Washington University School of Medicine
St Louis, Missouri

Jonathan Strosberg, MD
Professor
Department of GI Oncology
Moffitt Cancer Center and Research Institute
Tampa, Florida

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program: 
https://bit.ly/4mjNPfy

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:

• Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules
• Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations
• Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations

Presenters:

Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit, Michigan

Shawna Kraft, PharmD, BCOP
Clinical Pharmacist, Specialist
Michigan Medicine, Rogel Cancer Center
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Resources:
Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.

Program Abstracts: 

• POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL
• ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL
• CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL
• InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL
• SHR2554: Oral EZH2 Inhibitor in R/R PTCL
• SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL

Presenters:

Max S. Topp, MD
Head of Hematology and Clinical CAR-T Program Lead
Associated Professor
Medinische Klinik und Poliklinkik II
University of Wurzburg
Wurzburg, Germany

Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Alma Mater Studiorum- University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Link to full program:
https://bit.ly/4obcJPI

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: 

• DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancer
• ASCENT-04/KEYNOTE-D19: phase III trial of first-line sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in PD-L1–positive advanced TNBC
• SERENA-6: phase III trial of ctDNA-guided switch to camizestrant plus CDK4/6i vs continued AI plus CDK4/6i following ESR1 mutation emergence in HR-positive/HER2-negative advanced breast cancer
• INAVO120: OS from phase III study of first-line inavolisib/PBO plus palbociclib plus fulvestrant in PIK3CA-mutated, HR-positive/HER2-negative, endocrine-resistant advanced breast cancer

Presenters:

Kevin Kalinsky, MD, MS, FASCO​
Professor of Medicine​
Louisa and Rand Glenn Family Chair in Breast Cancer Research​
Winship Cancer Institute​
Emory University
Atlanta, Georgia​

Sara M. Tolaney, MD, MPH​
Chief, Breast Oncology​
Dana-Farber Cancer Institute​
Associate Professor of Medicine​
Harvard Medical School​
Boston, Massachusetts​

Content based on an online CME program supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

Link to full program: 
https://bit.ly/4lFS4BC

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:

• Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancer
• Interactive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancer
• Outcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs
   

Program faculty:

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts 

Shipra Gandhi, MD, MS
Associate Professor
Director, Breast Translational Research
Glenn Family Breast Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Resources:
To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.

Presenters:

Eytan M. Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Eunice S. Wang, MD
Chief, Leukemia Service
Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Link to full program: 
https://bit.ly/4f4an0O

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:

• The randomized phase III FLAIR trial
• The randomized phase III SEQUOIA trial
• The randomized phase III BRUIN CLL-321 trial
   

Presenters:

James Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
MUSC Hollings Cancer Center
Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina

Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Link to full program: 
https://bit.ly/3H2EcSX

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:

• Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC
• Overview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab) 
• Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCC

Program faculty:

Joseph W. Franses, MD, PhD
Assistant Professor of Medicine
Section of Hematology-Oncology
University of Chicago
Chicago, Illinois

Neehar Parikh, MD, MS
Associate Professor
Li Ka Shing Research Professor of Hepatology
Clinical Director of Hepatology
Medical Director, Liver Tumor Program
Division of Gastroenterology & Hepatology
University of Michigan
Ann Arbor, Michigan

Mark Yarchoan, MD
Associate Professor
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland
 

Resources:
To access the resources associated with this podcast discussion, please visit the program page to access a recording from a live webinar and a frequently-asked questions commentary on this topic.

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 2025.

• The Landscape of Frontline Options in HL
• Special Considerations for Older Patients
• Special Considerations for Pediatric Patients
• Future Directions in HL

Presenters:

Jonathan W. Friedberg, MD
Director, Wilmot Cancer Institute
Samuel Durand Professor of Medicine and Oncology
University of Rochester
Rochester, New York

Alex F. Herrera, MD
Chief, Division of Lymphoma
Professor, Department of Hematology and Hematopoietic Cell Transplantation
Medical Director of the City of Hope Clinical Trials Office
Associate Medical Director of the Briskin Center for Clinical Research
City of Hope Medical Center
Duarte, California

Kara M. Kelly, MD
Waldemar J. Kaminski Endowed Chair of Pediatrics
Roswell Park Comprehensive Cancer Center
Division Chief and Professor of Pediatrics
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Buffalo, New York

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to CME: Claim Credit
https://bit.ly/3TQ0M45

Link to full program: 
https://bit.ly/4eV8AuW

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: 

• Mechanistic differences between CELMoDs and IMiDs
• Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma
• The clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myeloma

Presenters:

Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FACP
Director, Judy and Bernard Briskin Center for Myeloma
Executive Director of Hematology
City of Hope Orange County
Professor of Hematology/HCT
City of Hope Cancer Center
Irvine, California

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program: 
https://bit.ly/3IwbslQ